KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Income from Non-Controlling Interests (2017 - 2025)

Teva Pharmaceutical Industries' Income from Non-Controlling Interests history spans 9 years, with the latest figure at $1.0 million for Q3 2025.

  • For the quarter ending Q3 2025, Income from Non-Controlling Interests fell 97.87% year-over-year to $1.0 million, compared with a TTM value of $7.0 million through Dec 2025, up 102.19%, and an annual FY2025 reading of $7.0 million, up 102.19% over the prior year.
  • Income from Non-Controlling Interests for Q3 2025 was $1.0 million at Teva Pharmaceutical Industries, down from $6.0 million in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was $47.0 million in Q3 2024, with the low at -$280.0 million in Q1 2024.
  • Average Income from Non-Controlling Interests over 5 years is -$21.3 million, with a median of $3.0 million recorded in 2022.
  • Biggest YoY gain for Income from Non-Controlling Interests was 487.5% in 2024; the steepest drop was 1550.0% in 2024.
  • Tracing TEVA's Income from Non-Controlling Interests over 5 years: stood at $7.0 million in 2021, then plummeted by 557.14% to -$32.0 million in 2022, then surged by 112.5% to $4.0 million in 2023, then plummeted by 1550.0% to -$58.0 million in 2024, then surged by 101.72% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Income from Non-Controlling Interests are $1.0 million (Q3 2025), $6.0 million (Q1 2025), and -$58.0 million (Q4 2024).